RxDoctor Payments Data

Kodlipet Dharmashankar, MD

Cardiovascular Disease · Texas City, TXNPI 1154405116

Payments from drug & device makers

$8,996in general payments, 2019–2025

Across 257 payments — averaging $35.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Boston Scientific$2K
  • Medtronic$1K
  • Novartis$369
  • Merck$308
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$265
  • plus $2K from 35 others

What the payments were for

  • Travel & lodging$5056%
  • Food & beverage$8,46994%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,996 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$303,574
Medicare patients
648
Services billed
3,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban120$113,932
XareltoRivaroxaban21$27,725
EntrestoSacubitril/Valsartan34$24,359
BrilintaTicagrelor13$15,089
ClopidogrelClopidogrel Bisulfate122$1,433
Metoprolol Tartrate148$1,038
Metoprolol Succinate77$930
Rosuvastatin Calcium38$910
Amiodarone Hcl19$903
Furosemide126$840
Carvedilol112$764
Atorvastatin Calcium102$721
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$614
Losartan Potassium80$566
Amlodipine Besylate86$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$113,932120 claims
Johnson & JohnsonXarelto$202$27,72521 claims
NovartisEntresto$369$24,35934 claims
AstraZenecaBrilinta$55$15,08913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Texas City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →